Milestone Scientific's Vaximm Appoints Dr. Wieckowski as Chief Scientific Officer for Cancer Advancements
- Vaximm AG appoints Dr. Sébastien Wieckowski as Chief Scientific Officer to enhance oral T-cell immunotherapies for cancer.
- Dr. Wieckowski's expertise in immunology and data science will optimize Vaximm's technologies and accelerate drug discovery.
- His leadership aims to broaden Vaximm's impact in oncology and beyond, aligning with OSR Holdings' strategic goals.
Vaximm AG Strengthens Leadership with Appointment of Dr. Sébastien Wieckowski as Chief Scientific Officer
Vaximm AG, a subsidiary of OSR Holdings, Inc., has recently announced the appointment of Dr. Sébastien Wieckowski as Chief Scientific Officer, effective January 16, 2026. This strategic leadership change is anticipated to significantly bolster Vaximm’s efforts in advancing its oral T-cell immunotherapies for cancer. Dr. Wieckowski brings a wealth of experience in immunology and data science, which will be instrumental in optimizing the company's proprietary technologies and accelerating drug discovery processes. His appointment comes at a pivotal moment as Vaximm prepares to move its lead candidate, VXM01, into later-stage clinical trials while also seeking new therapeutic targets.
Dr. Andreas Niethammer, CEO of Vaximm, has expressed strong confidence in Dr. Wieckowski’s capabilities, noting his contributions to the company since 2016. Niethammer emphasizes that Dr. Wieckowski’s strategic vision and execution will be crucial as Vaximm navigates the complexities of clinical development. The CEO’s enthusiasm reflects the company's commitment to advancing innovative treatments in oncology, leveraging Dr. Wieckowski's expertise in both immunology and data science to enhance their clinical programs. Dr. Constance Höfer, CSO of OSR Holdings, also underscores the significance of Dr. Wieckowski's leadership in the ongoing development of VXM01, highlighting how his direction will enable a data-driven evolution of Vaximm’s platform.
Dr. Wieckowski himself articulates a clear vision that integrates deep immunological insights with advanced data analytics. His focus on developing next-generation therapies underscores a commitment to creating patient-centric solutions that prioritize safety and tolerability. As Vaximm aims to expand its capabilities beyond oncology, Dr. Wieckowski’s leadership is poised to enhance the company's strategic partnerships and collaborations in later stages of development, aligning with OSR Holdings' broader goals of advancing platform-driven assets. This appointment signifies a forward-thinking approach that could redefine Vaximm's position in the competitive landscape of cancer therapeutics.
In addition to Dr. Wieckowski's appointment, Vaximm's ongoing focus on innovation is evident through its commitment to exploring new therapeutic indications. By harnessing cutting-edge research and data-driven methodologies, the company aims to broaden its impact in both oncology and non-oncology areas, reflecting a holistic understanding of patient needs.
As the industry evolves, Vaximm stands ready to capitalize on emerging opportunities that align with its strategic vision, driven by a leadership team focused on scientific excellence and transformative therapies.